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Abstract 
Enterotoxigenic Escherichia coli (ETEC: F4) associated with post‑weaning diarrhea (PWD) in pigs has developed resist‑
ance against several antimicrobial families, leading to increased use of colistin sulfate (CS) for the treatment of this dis‑
ease. The objective of this study was to determine the efficacy of oral CS treatment in experimental PWD due to ETEC: 
F4 challenge and determine the effect of this challenge on CS intestinal absorption. In this study, 96 pigs were divided 
into two trials based on CS dose (100 000 or 50 000 IU/kg). Fecal shedding of ETEC: F4, total E. coli, and CS‑resistant  
E. coli, diarrhea scores, and weight changes were evaluated. Colistin sulfate plasma concentrations were determined 
by HPLC–MS/MS. Regardless of the dose, CS treatment resulted in a reduction of fecal ETEC: F4 and total E. coli shed‑
ding, and in diarrhea scores but only during the treatment period. However, CS treatment resulted in a slight increase 
in fecal shedding of CS resistant E. coli and did not prevent weight loss in challenged pigs. In addition, challenge with 
ETEC: F4 resulted in an increase of CS intestinal absorption. Our study is among the first to demonstrate that under 
controlled conditions, CS was effective in reducing fecal shedding of ETEC: F4 and total E. coli in experimental PWD. 
However, CS treatment was associated with a slight selection pressure on E. coli and did not prevent pig weight loss. 
Further studies are needed in field conditions, to better characterize CS therapeutic regimen efficacy and bacterial 
resistance dissemination.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Escherichia coli post-weaning diarrhea (PWD) is an eco-
nomically important disease in pig production worldwide 
[1–3]. This disease affects pigs mostly during the 2 weeks 
after weaning and is characterized by a reduction in feed 
intake, poor growth rate, diarrhea and mortality [3]. These 
disturbances are most commonly associated with the pro-
liferation of enterotoxigenic F4-positive E. coli (ETEC: F4) 
[3], the most predominant sero-virotypes being O149: LT: 
STb: F4 and O149: LT: STa: STb: F4 [3, 5]. Small intestine 
epithelial cell adhesion and subsequent colonization 
by ETEC: F4 is mediated by the F4 fimbriae via specific 
receptors (F4R), crucial in determining the susceptibility 
of pigs to ETEC infection [3, 4]. Because ETEC: F4 iso-
lates from PWD have shown a high frequency of resist-
ance to multiple antimicrobials [1, 5], therapeutic failure 
is common and alternative molecules need to be found. 
Colistin sulfate (CS), a cationic antimicrobial peptide, is 
one possible candidate for the treatment of PWD, which 
is approved for use in pigs in several countries [6, 7]. 
However, CS is not yet approved for use in pigs in other 
countries such as Canada and is used under veterinarian 
responsibility for the treatment of PWD [8].
The bactericidal effect of CS is the result of an electrostatic 
interaction between the cationic elements of CS and anionic 
lipopolysaccharide (LPS) molecules in the membrane of 
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Gram-negative bacteria, leading to the displacing of mag-
nesium (Mg2+) and calcium (Ca2+)—stabilizers of LPS mol-
ecules—from the LPS [9]. This process results in an increase 
in the permeability of the cell envelope, leakage of cell con-
tents, and subsequent cell death [10, 11].
Several studies from different countries have reported 
isolation from pigs of E. coli resistant to colistin [12–17]. 
The most common mechanisms of resistance to CS in 
E. coli are modifications of the LPS with the addition of 
positively charged groups, such as L-4-aminoarabinose 
(L-Ara4N) and/or phosphoethanolamine (pEtN) [18–20]. 
More recently, Liu et al. have demonstrated the presence 
of a stable plasmid mediated mcr-1 gene that encodes for 
E. coli colistin resistance [21].
In pigs, CS is mainly administered per os, at the rec-
ommended dose of 50 000 IU/kg body weight (bw) every 
12  h for a period of 3–5 consecutive days for the treat-
ment of intestinal infections caused by Enterobacte-
riaceae [6, 22]. However, this dose regimen is often not 
respected on farms [6]. Several reports have shown that 
the recommended dose [23–25] or duration [23, 25] of 
CS treatment is often surpassed.
In addition, the efficacy of CS at the dose of 50 000 IU/
kg for the clinical treatment of PWD has not been inves-
tigated and no data are available in the literature on the 
role of this therapeutic regimen in exacerbating of E. coli 
resistance in pigs. Several studies have confirmed that 
CS is poorly absorbed in pigs after oral administration 
[8, 22]. However, little is known of the effect of ETEC: F4 
infection with clinical PWD on CS intestinal absorption, 
following the use of CS in a conventional therapeutic reg-
imen. An increase of CS intestinal absorption could have 
an impact on the withdrawal time following oral admin-
istration of this antibiotic. Moreover, in countries where 
CS is approved in pig, this varies from 1 to 7 days [6].
Hence, the main objective of the present study was to 
evaluate the effect of CS treatment in an experimental 
PWD model on fecal ETEC: F4 and total E. coli, on E. coli 
resistance to CS, on fecal consistency, growth rates, and 
rectal body temperature of weaned pigs. In addition, the 
effect of ETEC: F4 infection on CS intestinal absorption 
levels was determined using a high-performance liquid 
chromatography coupled with tandem mass spectrom-
etry (HPLC–MS/MS).
Materials and methods
The experimental protocol (14-Rech-1729), was reviewed 
and approved by the Ethics Committee on Animal Use 
of the Faculty of Veterinary Medicine (FVM) of the Uni-
versity of Montreal, and it was performed in accordance 
with the guidelines of the Canadian Council on Animal 
Care (CCAC).
Animals, experimental design and housing
A total of 96 Duroc-Yorkshire-Landrace pigs were used 
to carry out the experiment, animals were housed at a 
biosecurity level 2 agro-environmental platform for farm 
animals of the FVM.
Pigs were selected based on the presence of the F4 
receptor gene by PCR–RFLP as previously described 
[26] at 4  days of age. Two trials of 48 pigs were con-
ducted using different doses of CS [100 000  IU/kg (trial 
1) or 50 000 IU/kg (trial 2)]. In each trial, four groups of 
12 pigs were constituted: challenged treated, challenged 
untreated, unchallenged treated, and unchallenged 
untreated.
After weaning (21  days old), pigs were fed a stand-
ard non-medicated ration for post-weaning pigs and 
had unlimited access to feed and water throughout the 
7 weeks of the study. The temperature of the room was 
kept at 24–26 °C. In both trials, challenged groups were 
placed in the same room, although each group (n = 12) 
was housed in a separate pen. The two unchallenged 
groups were placed in two different rooms. Each pen had 
a stainless-steel feeder and a low-pressure nipple drinker. 
In order to avoid contamination of control groups, bios-
ecurity measures were applied, including use and chang-
ing of boots, coveralls and gloves before entering each 
room.
ETEC: F4 Oral challenge and antimicrobial administration
For experimental infection of pigs, a nalidixic acid-resist-
ant (Nalr) variant of ETEC: F4 strain ECL8559 (O149: LT: 
STa: STb: East1: paa: hemβ: F4), kindly provided by the 
E. coli Laboratory as described previously [8], was used. 
The strain was passaged in a weaned pig to enhance its 
pathogenicity. A hemolytic, Nalr colony isolated from the 
feces of this pig was confirmed to be positive for O149 
and the virulence genes F4, STa, STb, LT by multiplex 
PCR as previously described [27]. This strain, designated 
ECL8559A, was used in the experimental challenge in 
this study. After 1-week of acclimatization, 28-day-old 
pigs in the challenge groups were orally gavaged with 
109 CFU of the ETEC: F4 strain in 5 mL of trypticase soy 
broth (Difco Laboratories, Inc., Detroit, MI, USA) follow-
ing the administration of 10 mL of CaCO3 to neutralize 
gastric acid.
Colistin sulfate (Bond & Beaulac Inc., QC, Canada) was 
administered by oral gavage in 5 mL of water using a pol-
yethylene tube attached to a syringe, at a dose of 100 000 
or 50 000 IU/kg in trials 1 and 2 respectively. CS adminis-
tration was started when at least two pigs from the chal-
lenged groups showed PWD symptoms (i.e. score 2 of 
diarrhea, lethargy and anorexia), and continued twice a 
day for 5 successive days.
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Fecal sampling and microbiological analysis
Fresh fecal samples were obtained from pigs using pre-
weighed sterile rectal swabs (Puritan Medical Products, 
Guilford, Maine, USA). Bacteriological examination of 
fecal samples was performed 1 day before and 1, 2, 3, 5, 6, 
7, 8, 10, 13, 20, 27, 36 days after oral challenge to evaluate 
fecal excretion of the challenge ETEC: F4 strain and total 
E. coli count. One millilitre of buffered peptone water 
solution (BPW) was added to each swab and selected 
dilutions were plated on MacConkey agar and 5% bovine 
blood agar plates containing nalidixic acid at 50  μg/mL 
(Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) 
to count the total E. coli population and the hemolytic 
challenge ETEC: F4 strain respectively, as previously 
described [8, 26]. In parallel, 5% bovine blood agar plates 
containing nalidixic acid at 50  μg/mL and CS at 2  μg/
mL and MacConkey agar plates containing CS at 2  μg/
mL were used to enumerate the CS resistant hemolytic 
challenge ETEC: F4 and total E. coli population respec-
tively. The plates were incubated aerobically for 24  h at 
37 °C. Isolates recovered from media containing 2 μg/mL 
of colistin were considered to be putative CS-resistant, as 
previously described [16]. All samples were processed on 
the day of collection. Rectal swabs were weighed before 
and after sampling of pigs for individual fecal material 
quantification.
The isolates on MacConkey agar were confirmed as 
E. coli by colony morphology and biochemical analysis 
[28]. Hemolytic colonies on blood agar were confirmed 
as ETEC: F4 by multiplex PCR using published primers 
[29–31]. The minimum inhibitory concentration (MIC) 
was determined as the lowest CS concentration that 
resulted in the inhibition of bacterial growth. The MIC 
was determined for the challenge strain before animal 
inoculation, and for confirmed E. coli isolates recovered 
from agar plates containing CS at 2  μg/mL after chal-
lenge. The MIC was carried out by microdilution method 
using a sterile 96-well polystyrene microplate, as previ-
ously described [8]. The MIC was only evaluated on iso-
lates from trial 2 (50 000  IU/kg), representing the most 
common dosage used in PWD treatment worldwide.
At 36  days post-challenge, pigs were euthanized and 
necropsies were performed.
Health status assessment
After the oral challenge, pigs were observed daily for 
signs of anorexia, lethargy and diarrhea. The severity of 
diarrhea was assessed visually by using a fecal consist-
ency scoring (0, normal; 1, soft feces; 2, mild diarrhea; 3, 
semi liquid diarrhea and 4, liquid diarrhea) as described 
by Jamalludeen et  al. [32]. The rectal body temperature 
was monitored daily using a digital thermometer.
Pigs were weighed individually using an electric scale 
prior to inoculation and at 6, 19 and 35 days after begin-
ning CS treatment.
Blood sampling and pharmacokinetic analysis
Blood samples (3  mL) were collected using potassium 
EDTA tubes, from the jugular vein of eight pigs in each 
treated group, challenged or not of the two trials, at 0.5, 
12, 24 and 48 h after the last CS oral administration on 
day 5.
Plasma was separated by centrifugation at 3000  g for 
10  min and stored at −20  °C prior to analysis. These 
samples were used to determine CS plasma concentra-
tions by high performance HPLC–MS/MS, in order to 
determine the slope of the terminal phase (λz). The λz 
was calculated as the negative of the slope of the log-
linear regression of the natural logarithm concentra-
tion–time curve during the terminal phase. The λz is an 
important parameter used to determine CS elimination 
half-life (T1/2), which is an index of drug persistence in 
the body [33]. Bioanalyses and pharmacokinetic analyses 
were performed as previously described [8]. The quan-
tification of CS was based on the peak area ratio of the 
analyte with the internal standard. A calibration curve 
was used for determining the concentration of CS in all 
unknown samples by comparing the peak area ratio of 
the unknown samples to a set of standard samples of 
known concentration. It is important to note that a lin-
ear regression (weighted 1/concentration) produced the 
best fit for the concentration–detector relationship and 
consequently, the change of CS ionization states had 
a minimal effect within the analytical range used. The 
method precision and accuracy was well within accept-
able figure of merits [34].
Statistical analysis
Bacterial counts and CS plasma concentrations were 
log10 transformed prior to data analysis to normal-
ize distributions. Total E. coli counts, ETEC: F4 counts, 
rectal temperature, and body weight were analyzed with 
repeated-measures ANOVA, with time as a within-
subject factor and group as the between-subject factor. 
A priori contrasts were performed to compare group 
means at different time periods and to compare pre- and 
post-infection means in each treatment. For these multi-
ple comparisons, the alpha level was adjusted downward 
using the Benjamini-Hochberg sequential procedure. A 
similar procedure was used to analyze CS plasma con-
centration to determine effect of ETEC: F4 oral challenge 
on CS intestinal absorption in pigs.
Ordinal diarrhea scores were analyzed with the 
Cochran-Mantel-Haenszel test at each time period.
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Statistical analyses were carried out with SAS v.9.4. 
(Cary, N.C.). The level of statistical significance was set at 
p < 0.05 for all analyses.
Results
During the acclimation period, none of the pigs in the 
two trials showed clinical signs of PWD. In trial 1, there 
were no deaths among pigs throughout the experiment. 
However, in trial 2, one pig in the challenged treated 
group died 2  days after the oral challenge and two pigs 
in the challenged untreated group died at 4 and 6  days 
after the challenge following presentation of a profuse 
diarrhea (score 4). Necropsies were not performed for 
dead pigs, due to the presence of advanced post-mortem 
bacterial invasion. However, no mortality occurred in the 
unchallenged groups of the two trials.
As the two trials were not performed at the same time for 
technical reasons, the two CS doses were only compared 
when the course of infection was similar for the challenged 
untreated groups (control groups) of the two trials. Thus, 
the effect of CS dose was compared between the two trials 
only for shedding of ETEC: F4 and total E. coli.
Analysis of ETEC: F4 bacterial shedding (trial 1 and trial 2)
After the challenge, there was a rapid initial increase in 
ETEC: F4 shedding in the feces of all challenged pigs 
(Figure 1). There were no significant differences between 
the groups in the recovery of ETEC: F4 on the first day 
post challenge but on the following day after CS first 
dose administration (d1), there was a reduction in the 
treated group compared to the untreated group in the 
trial 2 (p < 0.0001). In both trials, CS treatment resulted 
in a significant reduction in fecal ETEC: F4 shedding 
between d2 and d6 (p < 0.0001), and the levels of ETEC: 
F4 dropped below our detection limit for most pigs 
between d4 and d6. However, after d6, fecal excretion 
of ETEC: F4 increased in the treated groups to the same 
level of excretion as in the untreated groups, with a sig-
nificant increase at d19 in trial 2 (p = 0.007). However, a 
significant reduction in fecal excretion of ETEC: F4 was 
observed in trial 2 compared to trial 1 between d1 and 
d3, inclusively (p < 0.0001) (Figure 1).
In the two trials, during the acclimation period, no E. 
coli were isolated on the blood agar plates containing 
nalidixic acid from any fecal samples, nor from unchal-
lenged pigs throughout the experiment.
Analysis of shedding of total E. coli population (trial 1 
and trial 2)
Mean total fecal E. coli counts of the challenged treated 
group and the challenged untreated group were simi-
lar on d-3 (before challenge) in each trial and increased 
in both challenged groups of the two trials on d-1 (24 h 
after challenge) (Additional file  1). However, the ETEC: 
F4 challenge did not significantly increase the total E. coli 
population fecal shedding.
Colistin sulfate treatment at a dose of 100 000  IU/
kg (trial 1) induced a significant reduction in fecal total 
E. coli shedding between d1 and d5 in the challenged 
treated group compared to the challenged untreated 
group (p < 0.0001) (Additional file 1). The same therapeu-
tic regimen (100 000 IU/kg) also resulted in a significant 
reduction in fecal total E. coli shedding between d2 and 
d6 in the unchallenged treated groups compared to the 
unchallenged untreated group (p  <  0.0001) (Additional 
file 2).
Colistin sulfate treatment at a dose of 50 000 IU/kg 
(trial 2) induced a significant reduction in fecal total 
Figure 1 Evolution of fecal ETEC: F4 bacterial counts (mean ± standard deviation [SD]). Challenge was performed at d‑2 and treat‑
ment with colistin sulfate (CS) at a dose of 100 000 IU/kg (trial 1) or 50 000 IU/kg (trial 2) was started at d0 (36 h post challenge) and administered 
twice daily for a period of 5 days. In the two trials, CS treatment resulted in a significant reduction in fecal ETEC: F4 shedding between d2 and d6 
(p < 0.0001). A significantly lower fecal excretion of ETEC: F4 was observed in trial 2 compared to trial 1 between d1 and d3 inclusive (p < 0.0001).
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E. coli shedding between d1 and d6 in the challenged 
treated group compared to the challenged untreated 
group (p < 0.0007) (Additional file 1). This therapeu-
tic regimen also resulted in a significant reduction 
in fecal total E. coli shedding between d2 and d5 in 
the unchallenged treated group compared to the 
unchallenged untreated group (p  <  0.0001) (Addi-
tional file 2). However, in both trials, starting from d7 
(2 days after CS cessation), fecal excretion of total E. 
coli increased in the treated groups to reach the same 
level of excretion as in the untreated groups (Addi-
tional files 1 and 2).
A significant reduction in fecal excretion of total E. coli 
was observed in trial 2 compared to trial 1 at d2 and d3 
inclusively (p = 0.003 and p < 0.0001, respectively). Con-
sequently, the highest reduction in total E. coli fecal shed-
ding was observed in trial 2 (lower dose) between d2 and 
d3 (Additional files 1 and 2).
Isolation of E. coli resistant to colistin sulfate
In trial 2, before the challenge period and exposure to CS 
at a dose of 50 000 IU/kg, fecal shedding of putative CS-
resistant E. coli in the challenged treated group and the 
untreated group was very similar, as shown by the ratios 
of log putative CS-resistant E. coli/log total E. coli (Addi-
tional file 3). A low number of cultivable resident putative 
CS resistant E. coli were observed in all pigs used in this 
study.
Following CS administration, there was a significant 
decrease in the total E. coli population (Additional file 1). 
From d2 post CS treatment, the challenged treated pigs 
demonstrated a slight increase (15%) in the proportion 
of putative CS-resistant E. coli compared with the chal-
lenged untreated pigs. This difference was observed 
throughout CS administration, being significant between 
d3 and d5 (p  <  0.0005) and gradually diminishing from 
the first day (day 6) of CS discontinuation (Additional 
file 3).
Among 80 putative CS resistant E. coli isolates on Mac-
Conkey plates, 72 were identified as E. coli by biochemi-
cal analyses, only one isolate being identified as ETEC: F4 
by multiplex PCR. No putative CS resistant colonies were 
isolated on blood agar plates containing nalidixic acid.
Among 72 putative CS resistant E. coli isolates, 9 (8 in 
the challenged treated group and one in the challenged 
untreated group) were confirmed resistant to CS with an 
MIC >2 μg/mL (Table 1).
The CS resistant ETEC: F4 isolate, probably originating 
from the challenge strain as it was confirmed by multiplex 
PCR, demonstrated an MIC of 8 μg/mL, as compared to 
<0.06  μg/mL for the challenge strain (ECL8559A). This 
ETEC: F4 isolate was found in the challenged untreated 
group 4 days after the oral challenge (Table 1).
Analysis of health status and growth performance
Prior to bacterial challenge, no pig in either trial showed 
any indication of severe diarrhea or loose stools. None of 
the unchallenged pigs in the two trials showed any illness 
or diarrhea during the experiment.
Following challenge, all challenged pigs in the two tri-
als showed high diarrhea scores with no statistically sig-
nificant difference between treated and untreated groups 
(Figure 2; Additional file 4). After 2 days of CS adminis-
tration (d2), diarrhea scores were significantly decreased 
in the challenged treated compared to the challenged 
untreated groups, and shown in Figure  2 for trial 2 
(p  <  0.0001). The decrease was also observed at d3 and 
d4 in the two trials (Figure 2; Additional file 4). From d5 
(6 days post challenge), diarrhea scores in the challenged 
untreated groups of both trials decreased and no statisti-
cally significant difference in the diarrhea scores between 
challenged untreated and challenged treated groups was 
observed in either trial.
Some challenged pigs in both trials developed hypo-
thermia, several days post challenge, occasionally fol-
lowed by death.
The body weight of the pigs in trial 2 in the pre-
challenge period did not differ among the four groups 
(p  >  0.71). Following oral challenge with ETEC: F4 
and CS treatment discontinuation (d6), no difference 
was detected in the body weight of all pigs in both tri-
als (Figures 3 and 4) with p > 0.05 and p > 0.07 for tri-
als 1 and 2 respectively. After 2  weeks of CS treatment 
discontinuation (d19), a significantly higher body weight 
was observed in trial 1 for the unchallenged untreated 
(control) compared to the challenged untreated group 
(p  <  0.001) (Figure  3). However, in trial 2 for the same 
time (d19), the unchallenged treated group presented 
a higher mean weight compared to the challenged 
untreated group (p < 0.001) (Figure 4). After 30 days of 
CS treatment discontinuation (d35) in both trials, the 
unchallenged treated and the control groups presented 
a higher mean weight compared to the challenged 
untreated groups (Figures  3  and 4). In addition, in trial 
2 at d35, the unchallenged treated group and the control 
group presented a higher mean weight compared to the 
challenged treated group, with p < 0.0001. 
Overall, the ETEC: F4 challenge resulted in decreased 
growth rate of the challenged groups in both trials and 
treatment with CS at the doses used in this study did not 
affect this decreased growth rate.
Quantification of plasma concentration of colistin sulfate 
and pharmacokinetic analysis
In order to determine whether ETEC: F4 challenge 
affects CS intestinal absorption, an HPLC–MS/MS was 
used for CS quantification in pig plasma. The lower 
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limit of quantitation (LLOQ) of our method was 1  ng/
mL of plasma. The pharmacokinetic analyses were per-
formed using a non-compartmental model. In both tri-
als, CS plasma concentrations were detected in all treated 
groups (challenged or not), although they were higher in 
challenged treated groups compared to the unchallenged 
treated groups for all sampling times (Figure 5).
In the challenged treated groups, the mean of Cmax 
(± SD) (the observed maximum plasma concentration of 
CS) was 338.3 (±676.37) and 122.3 (±161.97) ng/mL at 
0.5 h post CS treatment discontinuation in trials 1 and 2 
respectively (Figure 5). In trial 1, at 0.5, 12 and 24 h after 
CS treatment discontinuation, CS plasma concentrations 
were statistically higher in the challenged treated group 
compared to the unchallenged treated group with 
p < 0.001, p < 0.0001, and p < 0.001 respectively. The same 
finding was observed in trial 2, the CS plasma concentra-
tions were higher in challenged treated compared to the 
unchallenged treated group at 0.5  h (p  <  0.001), and at 
12  h (p =  0.04). Thus, ETEC: F4 oral challenge exacer-
bated the intestinal absorption of CS in challenged com-
pared to unchallenged weaned pigs. In both trials, at 48 h 
following the last CS administration, plasma concentra-
tions were below the LLOQ of our method. We were not 
able to determine the λz and T1/2 of CS following its oral 
administration even in challenged treated pigs. Based on 
Table 1 Distribution of minimal inhibitory concentrations of porcine CS resistant E. coli isolates in trial 2
D3 = 3 days post CS treatment; D11 = 11 days post CS treatment; D4 = 4 days post challenge; D1 = 1 day post CS treatment.
The isolates with MIC values higher than resistance breakpoint (MIC > 2 μg/mL) as described by Li et al. [45] were considered resistant.
MIC of ECL8559A <0.06 μg/mL.
CU: challenged untreated; CT: challenged treated.
a Isolate confirmed ETEC: F4 by multiplex PCR.
Colistin sulfate MIC values (μg/mL)
Isolates Time Groups 0.06 0.12 0.25 0.5 1 2 4 8 16 32
M4A3 D3 CT +
M4B3 D3 CT +
M4C3 D3 CT +
M4D3 D3 CT +
M6A11 D11 CT +
M6C11 D11 CT +
M6B11 D11 CT +
L10A4a D4 CU +
L1B1 D1 CT +
Figure 2 Mean diarrhea score (±standard deviation [SD]) of weaned pigs challenged with ETEC: F4. Challenge was performed at d‑2 
and treatment with colistin sulfate (CS) at the dose of 50 000 IU/kg (trial 2) was started at d0 (36 h post challenge) and administered twice daily for 
a period of 5 days. Treatment with oral CS resulted in a statistically significant reduction in the diarrhea score of the challenged treated group com‑
pared to the challenged untreated group (p < 0.0001) between d2 and d4. Mean diarrhea score = sum of daily diarrhea score/number of animals.  
*: p < 0.0001.
Page 7 of 11Rhouma et al. Vet Res  (2016) 47:58 
our sampling plan it was not possible to characterize the 
CS elimination phase and make a linear regression of the 
last CS plasma concentrations.
Discussion
The aim of the present study was to evaluate the impact 
of CS on the E. coli populations and pig health status in 
experimental E. coli-induced diarrhea in weaned pigs. 
We also studied the impact of ETEC: F4 oral challenge on 
CS intestinal absorption level in pigs using a highly sensi-
tivity analytical method (HPLC–MS/MS).
The duration of the experiment was 35  days in each 
trial, to cover the withdrawal period of 30  days applied 
in Canada for CS in pig farms. Indeed, in the absence of 
scientific explanation for the difference in the withdrawal 
period for CS oral formulations in pigs between countries 
[6], veterinarians use this long time period of 30 days as a 
safety measure for consumer protection against potential 
CS chemical residues in pig meat.
We used two doses of CS in our study in order to more 
closely reflect farm practices. In fact, the lower dose (50 
000 IU/kg) is the recommended therapeutic dose in pigs, 
whereas the higher dose (100 000 IU/kg) was used to take 
into consideration a more realistic portrait of CS use on 
pig farms, where this antibiotic is often overdosed [23], 
and the social rank and heterogeneity observed among 
pigs in the same pens which may increase antimicrobial 
consumption for some pigs [35].
In the current study, maximum ETEC: F4 shedding and 
diarrhea scores were observed one-day post challenge. 
Figure 3 Evolution of body weight in pigs receiving colistin sulfate (CS) orally at a dose of 100 000 IU/kg (mean ± standard deviation 
[SD]). Challenge was performed at d‑2 and treatment with colistin sulfate (CS) at the dose of 100 000 IU/kg. For each sampling time, means with 
different letters on a given day are statistically different. At d6 there was no significant difference between groups.
Figure 4 Evolution of body weight in pigs receiving colistin sulfate (CS) orally at a dose of 50 000 IU/kg (mean ± standard deviation 
[SD]). Challenge was performed at d‑2 and treatment with colistin sulfate (CS) at the dose of 50 000 IU/kg. For each sampling time, means with 
different letters on a given day are statistically different. At d‑3 and d‑6 there was no significant difference between groups.
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This result is consistent with other experimental stud-
ies in which a higher frequency of watery diarrhea was 
observed after the first day of the ETEC: F4 oral challenge 
[36, 37].
In our study, regardless of the dose, CS treatment led to 
a decrease of nearly 4 log cfu/g in fecal shedding of ETEC: 
F4 and total E. coli, but only during the treatment period. 
This finding corroborates the study of Torrallardona et al. 
who showed that the use of CS at a dose of 300  mg/kg 
of diet in the treatment of weanling pigs challenged with 
E. coli K99 for a period of 7 or 14  days was associated 
with a reduction of the number of E. coli in both ileal and 
cecal digesta by 5.30 and 4.38 log cfu/g, respectively [38]. 
In our study, the effect of CS on the decrease of ETEC: 
F4 and total E. coli population was greater with the low 
dose of CS (50 000  IU/kg) used in trial 2. This finding 
is in disagreement with the known pharmacodynamics 
(PD) of CS as an antibiotic that exhibits its bactericidal 
activity in a concentration-dependent manner in  vitro 
[22]. However, Lin et al. reported that CS bioavailability 
after an intramuscular (IM) administration in pigs, was 
inversely proportional with the administered CS doses, 
with a systemic bioavailability of 95.94 and 88.45% for 2.5 
and 5 mg/kg bw respectively [39].
In the current study, no difference was noted between 
low and high CS doses given to pigs, regarding E. coli 
recovery and on health status. Nevertheless, it would 
have been interesting to quantify colistin in pig gut, to 
link the microbiological effects determined to the real CS 
concentrations in intestinal segments. However, for logis-
tic reasons associated with the design of the experiment 
and due to the low number of pigs in each group, it was 
not possible to sacrifice animals to recover the digestive 
contents, in this study.
In the present study, after CS treatment discontinu-
ation in the two trials, there was no difference in fecal 
shedding of ETEC: F4, total E. coli population, and diar-
rhea scores between challenged treated and challenged 
untreated groups. However, it should be noted that our 
experiment was carried out in controlled conditions, and 
that the outcome of CS treatment may differ during natu-
ral infections in farm conditions associated with specific 
factors such as livestock management, presence of other 
infections in the farm, feed additives, vaccination or 
other factors.
In our study, 12.5% of E. coli isolates originating from 
growth on MacConkey agar plates with 2  μg/mL of CS 
were confirmed resistant to colistin, most (8/9) follow-
ing the treatment with CS at 50 000 IU/kg, suggesting a 
CS selection pressure on E. coli. Our results corroborate 
those of Boyen et al. who determined that approximately 
10% of the 157 investigated porcine E. coli isolates from 
sick pigs showed resistance to colistin [16]. However, it 
is not clear whether sampled animals were treated with 
colistin in this study. On the other hand, the MICs of CS 
E. coli resistant isolates determined in our study were in 
the same range as those of resistant E. coli isolated from 
sick pigs in farm conditions [13, 16].
Figure 5 Evolution of plasma CS concentrations over time in pigs challenged with an ETEC: F4 strain and receiving colistin sulfate 
(CS) orally (mean ± standard deviation [SD]). Colistin sulfate concentrations were obtained by HPLC–MS/MS after 0.5, 12, 24 and 48 h of CS 
treatment discontinuation at a therapy regimen of 100 000 IU/kg (trial 1) or 50 000 IU/kg (trial 2). In trial 1, at 0.5, 12 and 24 h, CS concentrations 
were statistically higher in the challenged treated group compared to the unchallenged treated group with p < 0.001, p < 0.0001 and p < 0.001 
respectively. In trial 2, at 0.5 and 12 h, CS concentration was statistically higher in the challenged treated group compared to the unchallenged 
treated group with p < 0.001 and p = 0.04 respectively (n = 8 per group).
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In the present study, the CS resistance was observed 
in 3 E. coli isolates even 6  days after CS treatment dis-
continuation, and in an isolate confirmed ETEC: F4 in 
the challenged untreated group 4 days after the oral chal-
lenge. Further investigations are ongoing to explain if this 
CS resistance is associated with chromosomal mutations 
or a plasmid resistance gene, and to determine the ori-
gin of the higher MIC observed for the ETEC: F4 isolate 
compared to the challenge strain by determining of its 
natural mutation rate.
Although we observed a lower proportion of CS E. coli 
resistant isolates than reported by other authors [12, 40], 
it is premature to confirm that the use of this CS regimen 
in pigs is associated with a low resistance among E. coli. 
It would be interesting to determine in a future study the 
effect of CS in a mass treatment (drinking water or in 
feed) on CS resistance in E. coli in pig farm conditions 
and following a repetitive CS treatment.
In our study, the MacConkey agar plates supple-
mented with 2  μg/mL of CS overestimated the number 
of resistant E. coli as only a small percentage of the E. coli 
recovered from these MacConkey agar plates could be 
confirmed resistant to CS by MIC determination using 
Mueller–Hinton broth media. This finding may be due 
to the culture media change between the two experi-
ments as well as the difference in the matrix used: fecal 
material for MacConkey agar plates versus pure culture 
for Mueller–Hinton. In our study, the use of the MacCo-
nkey supplemented with 2  μg/mL of CS served mostly 
as a screening step for reducing the numbers of isolates 
potentially sensitive to CS and thus limiting the number 
of isolates to be tested on Mueller–Hinton for CS resist-
ance confirmation. Our study underlines the importance 
of confirming putative CS isolates on Mueller–Hinton 
CMI determination when non-standardized culture 
media are used for assessing the resistance levels of a 
given bacterial population.
In the present study, a growth retardation was 
observed in surviving animals of the challenged groups 
compared with the unchallenged groups in the two tri-
als. This finding corroborates the study of Bontempo 
et  al. who showed that E. coli challenge significantly 
impairs performance, resulting in a reduction of aver-
age daily gain for pigs [41]. Colistin sulfate treatment in 
the two trials did not prevent pig weight losses in chal-
lenged treated compared to challenged untreated pigs. 
In addition, we have not noticed a difference in pig body 
weight between unchallenged treated and unchallenged 
untreated groups in both trials. To the best of our 
knowledge, our study is the first to report these results 
following an oral CS administration at 50 000 or 100 
000 IU/kg bw in pigs. Nevertheless, it will be interesting 
to investigate in a long-term field trial with more pigs 
and in field conditions the effect of CS therapeutic regi-
men on pig weight loss prevention in the post-weaning 
period.
In our study, ETEC: F4 oral challenge increased the 
passage of CS from the intestine to the blood in the chal-
lenged pigs compared to the unchallenged weaned pigs 
in the two trials. Several studies have shown that admin-
istration of bacterial lipopolysaccharide (LPS) results in 
the production and release of TNF-α and IL-1; these pro-
inflammatory cytokines increased epithelial tight junc-
tion permeability in vitro in Caco-2 cells [42]. In another 
study, it was demonstrated that IL-1, activated endothe-
lial cells (EC) to induce vascular leakage via loss of vas-
cular endothelial (VE)-cadherin [43]. The role of LPS 
release by the challenge ETEC: F4 strain in increasing 
pig intestinal tight junction permeability and pro-inflam-
matory cytokine production needs to be confirmed in a 
future study.
Our results demonstrated that E. coli intestinal infec-
tion in weaned pigs with clinical PWD symptoms, 
resulted in increased of CS intestinal absorption. This 
finding should be taken into consideration when deter-
mining CS withdrawal time, bearing in mind that with-
drawal times are mostly determined in healthy animals 
[44], even though antibiotics are currently used to treat 
clinically sick pigs.
In conclusion, this is the first report on the use of CS 
for the treatment of experimental E. coli-induced diar-
rhea in weaned pigs. In our study, we determined that 
under controlled conditions in pigs, CS reduced ETEC: 
F4 and E. coli fecal shedding and diarrhea scores during 
treatment period. However, CS treatment did not prevent 
pig weight losses due to the diarrhea and exerted a slight 
selection pressure on the CS resistant E. coli commensal 
population. In addition, we demonstrated that oral chal-
lenge of pigs using an ETEC: F4 strain increased passage 
of CS from the intestine to the blood. This observation 
should be taken into consideration when determining the 
oral CS withdrawal time in pigs.
A longer duration field trial investigation is recom-
mended to better understand the relationship between 
CS effectiveness and CS bacterial resistance following 
the use of oral CS in PWD control in commercial farm 
conditions and lead to a prudent use of antimicrobials in 
swine medicine.
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